OXIGENE PLANS CA4P TRIAL

Oxigene is planning a Phase II clinical trial evaluating its lead clinical candidate, Combretastatin A4P, in the treatment of Stage IIIa/IIIb non-small cell lung cancer (NSCLC). The company will evaluate Combretastatin A4P (CA4P), in combination with concurrent chemo-radiotherapy, a widely accepted standard in the U.S.

The trial will initially enroll approximately 12 patients to assess the tolerability of the protocol and to establish the recommended dose of intravenously administered CA4P. It will then proceed to compare approximately 66 patients who will be split into an investigational group and an active control group.

In other ongoing clinical trials, CA4P has been paired with chemotherapy or radiation therapy with no observed side effects beyond those typically experienced with either treatment.